Auna (AUNA) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
11 Mar, 2026Executive summary
Stabilized Mexico operations in Q4 2025, setting the stage for top-line and EBITDA growth in 2026, despite earlier volume losses; Peru outperformed with strong pricing mix and record low medical loss ratio, while Colombia delivered growth and improved cash flow through risk-sharing contracts.
Consolidated revenue for FY25 was S/4,385 million, flat year-over-year on a reported basis but up 4% FXN; Q4'25 revenue up 7% YoY to S/1,133 million, driven by strong growth in Peru and Colombia offsetting Mexico's challenges.
Adjusted net income reached S/136 million in Q4, up from S/36 million YoY; full-year adjusted net income more than doubled to S/336 million.
Free cash flow grew 35% YoY to S/582 million; year-end cash position up 42% to S/335 million, supporting liquidity.
Completed US$825 million debt refinancing, improving maturity profile, reducing interest expense, and maintaining leverage ratio at 3.6x.
Financial highlights
FY25 consolidated revenue: S/4,385 million (flat YoY reported, +4% FXN); Q4'25: S/1,133 million (+7% YoY); adjusted EBITDA for FY25: S/917 million (-8% YoY reported, -3% FXN); margin 20.9% (-1.7 p.p. YoY); Q4'25 adjusted EBITDA: S/220 million (-13% YoY), margin 19.5% (-4.5 p.p. YoY).
Adjusted net income: S/336 million for FY25 (+130% YoY); S/136 million for Q4'25.
Free cash flow: S/582 million (+35% YoY); end-of-period cash: S/335 million (+42% YoY).
Net finance costs in FY25 S/436 million vs S/609 million in FY24; excluding extraordinary items, down 18.2%.
Gross margin for FY25: 37.9% (-1.4 p.p. YoY).
Outlook and guidance
2026 revenue and adjusted EBITDA growth expected at 12% FXN, within a 10–14% range, driven by commercial momentum, operational execution, and disciplined cost management.
CapEx expected to remain at approximately 4% of revenue, focused on maintenance, infrastructure, and IT investments.
Guidance based on current macroeconomic and regulatory assumptions; subject to change if conditions shift.
Mexico and Peru identified as primary growth engines over the next five years.
Latest events from Auna
- Adjusted EBITDA up 31% and revenue up 18% year-over-year, with leverage ratio at 4.13x.AUNA
Q2 202423 Jan 2026 - Adjusted EBITDA up 23% YoY, leverage ratio at 3.7x, and OncoMexico pilot advancing.AUNA
Q3 202413 Jan 2026 - Healthcare group targets $1B NYSE offering to expand Latin American operations.AUNA
Registration Filing16 Dec 2025 - Healthcare group seeks up to $1B in NYSE-listed shares to fund growth in Latin America.AUNA
Registration Filing16 Dec 2025 - FY24 Adjusted EBITDA up 20.1% FXN, margin and net income improved, leverage at 3.6x.AUNA
Q4 20243 Dec 2025 - Peru's growth offset Mexico and Colombia's declines, sustaining profitability and stable leverage.AUNA
Q1 202526 Nov 2025 - Adjusted EBITDA up 5% FXN YoY; net income surged; leverage steady amid FX headwinds.AUNA
Q2 202523 Nov 2025 - Peru and Colombia grew, Mexico declined; leverage stable, refinancing done, Mexico recovery in 2026.AUNA
Q3 202521 Nov 2025